Back

The effects of empagliflozin on right ventricular adaptation to pressure overload

27 August 2023 (09:42 - 10:00)
Organised by: Logo
Congress Presentation Part of: Molecular approaches to the treatment of pulmonary hypertension Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Ms Julie Soerensen Axelsen

Aarhus University, Aarhus (Denmark)

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on molecular approaches to the treatment of pulmonary hypertension
Doctor P. Thistlethwaite (La Jolla, US)
Slides Video
Presentation thumbnail
Hemodynamic changes with pulmonary arterial hypertension targeted therapies: a meta-analysis of 3898 treatment-naive patients
Mr I. Farmakis (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Development of KER-012, a modified ActRIIB ligand trap, for the treatment of pulmonary arterial hypertension
Doctor S. Cooper (Lexington, US)
Abstract Slides Video
Presentation thumbnail
Effects of inhaled seralutinib on right ventricular-pulmonary arterial (RV-PA) coupling and right heart function in pulmonary arterial hypertension (PAH)
Doctor K. Tello (Giessen, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Molecular approaches to the treatment of pulmonary hypertension
Video

The Event

Event poster

ESC Congress 2023

27 August 2023 09:42 CET
You may be interested in
thumbnail
Congress Presentation
Empagliflozin halts deleterious right ventricular remodeling in a model of rats with right ventricular dysfunction
thumbnail
Congress Presentation
The effect of empagliflozin on right ventricular function in heart failure patients with reduced ejection fraction: analysis from the randomized empire hf clinical trial
thumbnail
Congress Session
Molecular approaches to the treatment of pulmonary hypertension

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources